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Background:Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) cause Parkinson disease.
Results: LRRK2 binds directly to three -tubulin isoforms at the luminal face of microtubules and suppresses -tubulin
acetylation. Interaction is weakened by the R1441G LRRK2 GTPase domain mutant.
Conclusion: LRRK2 modulates microtubule stability.
Significance: Deregulation of microtubule-dependent processes likely contribute to neurodegeneration in Parkinson disease.
Mutations in LRRK2, encoding the multifunctional protein
leucine-rich repeat kinase 2 (LRRK2), are a common cause of
Parkinson disease. LRRK2 has been suggested to influence the
cytoskeleton as LRRK2 mutants reduce neurite outgrowth and
cause an accumulation of hyperphosphorylatedTau. Thismight
cause alterations in the dynamic instability ofmicrotubules sug-
gested to contribute to the pathogenesis of Parkinson disease.
Here, we describe a direct interaction betweenLRRK2 and-tu-
bulin. This interaction is conferred by the LRRK2 Roc domain
and is disrupted by the familial R1441G mutation and artificial
Roc domain mutations that mimic autophosphorylation.
LRRK2 selectively interacts with three -tubulin isoforms:
TUBB, TUBB4, and TUBB6, one of which (TUBB4) is mutated
in the movement disorder dystonia type 4 (DYT4). Binding
specificity is determined by lysine 362 and alanine 364 of -tu-
bulin. Molecular modeling was used tomap the interaction sur-
face to the luminal face of microtubule protofibrils in close
proximity to the lysine 40 acetylation site in -tubulin. This
location is predicted to be poorly accessible within mature sta-
bilizedmicrotubules, but exposed in dynamicmicrotubule pop-
ulations. Consistent with this finding, endogenous LRRK2 dis-
plays a preferential localization to dynamicmicrotubuleswithin
growth cones, rather than adjacent axonalmicrotubule bundles.
This interaction is functionally relevant to microtubule dynam-
ics, asmouse embryonic fibroblasts derived fromLRRK2knock-
out mice display increased microtubule acetylation. Taken
together, our data shed light on thenature of theLRRK2-tubulin
interaction, and indicate that alterations in microtubule stabil-
ity caused by changes in LRRK2 might contribute to the patho-
genesis of Parkinson disease.
Mutations in LRRK2, encoding leucine-rich repeat kinase 2
(LRRK2)6 are a common cause of inherited Parkinson disease
(PD) (1, 2). Because LRRK2 mutation carriers present symp-
toms and brain pathology very similar to idiopathic PD (1–4),
understanding the biological role of LRRK2 could help to
uncover new therapeutic strategies for both inherited and spo-
radic cases. LRRK2 belongs to the ROCO family of proteins,
which are characterized by the unique combination of a Roc
(Ras of complex proteins) domain with intrinsic GTPase activ-
ity and a COR (C-terminal of Roc) domain. The combination of
a GTPase domain and a kinase domain suggests a complex role
for LRRK2 in cell signaling (5). Additional protein-protein
interaction domains, such as leucine-rich repeat (LRR) and
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WD40 propeller motifs suggest that LRRK2 has multiple pro-
tein interactors that potentially localize LRRK2 to different
subcellular compartments (1, 2, 4, 5). Althoughmany sequence
variants have been reported in LRRK2, dominant mutations
clearly segregating with PD are only found in the RocCOR tan-
demdomain or the kinase domain (1, 2, 4, 5). LRRK2 kinase and
GTPase activity are clearly important for the cytotoxicity and
neurite changes observedwith LRRK2mutants in cellularmod-
els (6–12). However, the precise mechanisms by which LRRK2
mediates these events remain elusive.
One newly emerging theme is the interaction between
LRRK2 and the cytoskeleton. For example, LRRK2 has been
shown to interact with microtubules (MTs) (13–23) and in-
fluence MAPK and Wnt signaling pathways (19, 24–29).
Increased phosphorylation of the MT-associated protein
(MAP) Tau, which has been implicated in the pathogenesis of
PD in recent genome-wide screens (30, 31), is seen in several
animal models expressing LRRK2 mutants (28, 32, 33). There-
fore LRRK2 mutations might influence MT dynamics, which
would be predicted to play a role in synaptic and axonal degen-
eration as observed in postmortem brains of PD patients (34).
Here, we demonstrate a specific and direct interaction
between LRRK2 and three -tubulin isoforms that is mediated
by the LRRK2 Roc domain and -tubulin C termini. We dem-
onstrate that this interaction is dependent on guanidine nucle-
otide binding and modulated by Roc domain autophosphory-
lation and disrupted by the pathogenic LRRK2 mutation
R1441G. We also show that lysine 362 (Lys-362) and alanine
364 (Ala-364) in TUBB and TUBB4 underlie the isoform spec-
ificity of the LRRK2--tubulin interaction.Molecularmodeling
indicates that Lys-362 is present on an interaction surface in
the lumen of MT filaments close to the lysine 40 (Lys-40)
acetylation site in -tubulin. Corroborating this finding,
LRRK2 knock-out mouse embryonic fibroblasts (MEFs)
show increased tubulin acetylation. Last, we demonstrate
that LRRK2 co-localizes with highly dynamic cytoskeletal
structures in dopaminergic cells, and that LRRK2 overex-
pression and mutation impacts upon the morphology of
growth cones. Taken together, these data suggest a role for
LRRK2 in the regulation of cytoskeletal dynamics with impli-
cations for the pathogenesis of PD.
EXPERIMENTAL PROCEDURES
ExpressionConstructs and Site-directedMutagenesis—-Tu-
bulin cDNAs were amplified from human whole brain first-
strand cDNA (Clontech) using Pfx DNA polymerase (Invitro-
gen) and cloned into the YTH vector pACT2 (Clontech), or the
mammalian expression vector pRK5FLAG. Cloning resulted in
an in-frame fusion of the LexA DNA binding domain (LexA-
BD; vector pDS-BAIT), GAL4 activation domain (GAL-AD;
vector pACT2), or FLAG epitope tags to the N termini of all
expressed proteins. Vectors encoding the LRRK2 Roc domain,
COR domain, and RocCOR tandem domain in the pDS BAIT
plasmid (Dualsystems Biotech), and full-length myc-tagged
LRRK2 in the pRK5 mammalian expression vector, have been
described previously (19). Lentiviral plasmids encoding EGFP-
tagged LRRK2 wild-type and G2019S were generated excising
the 3FLAG tag from the pCHMWS-3FLAG-LRRK2 con-
structs (35, 36) via restriction with NheI and BamHI and an
EGFP sequence (excised from the peGFP-C1 plasmid using
NheI and BglII) was ligated into place, yielding the pCHMWS-
eGFP-LRRK2 wild-type and G2019S lentiviral vector plasmids.
Mutations were generated using the QuikChange site-directed
mutagenesis kit (Agilent). All constructs were verified by DNA
sequencing.
Yeast Two-hybrid Assays—The yeast strain L40 (Invitrogen)
was co-transformed with wild-type and mutant pDS LRRK2
RocCOR, Roc, or COR bait constructs together with wild-type
or mutant pACT2--tubulin prey constructs encoding the C
termini of tubulins from Phe-317 to the stop codon. Transfor-
mations were plated on selective dropout media lacking leu-
cine, tryptophan, and histidine supplemented with 0.5 mM
3-Amino-1,2,4-triazole (for suppression of “leaky” histidine
expression) for nutritional selection, or leucine and tryptophan
for transformation controls. After incubation at 30 °C for 3–6
days to allow prototropic colonies to emerge, LacZ reporter
gene assays were performed as previously described (37).
Quantitative YTH assays were performed by resuspending
cell pellets in Z-buffer containing 40 mM -mercaptoethanol
followed by lysis in 0.1% (w/v) SDS and 0.1% (v/v) chloroform.
All protein interactions were assayed in 3–4 independent
experiments in triplicate. After addition of chloropheno-red--
D-galactopyranoside the color change was recorded at 540 nm
and readings adjusted for turbidity of the yeast suspension at
620 nm. The background signal (bait  empty pACT2 vector)
was subtracted from each reading and values were normalized
to the wild-type RocCOR response, which was set at 100%.
Cell Culture, Co-immunoprecipitation, andWestern Blotting
of HEK293 Cells—HEK293 cells (ATCCCRL1573) were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mentedwith 10% (v/v) fetal bovine serum, 2mM glutamine, 100
units/ml of penicillinG, and 100g/ml of streptomycin at 37 °C
in 95% air, 5% CO2. Exponentially growing cells were trans-
fected with constructs encoding epitope-tagged -tubulin
and LRRK2 using Lipofectamine LTX reagent (Invitrogen).
HEK293 cells were harvested 48 h post-transfection, and lysed
in a solution containing 150 mM NaCl, 50 mM Tris (pH 7.5), 5
mM EDTA (pH 8), 0.25% (v/v) Nonidet P-40/complete protease
inhibitor mixture (Roche Applied Science). Following centrifu-
gation (4 °C, 15 min, 16,000  g) 1 ml of cell lysate containing
700g of proteinwas added to 40l of anti-FLAGM2affinity
gel (Sigma) and incubated overnight at 4 °C on a turning disk.
The affinity gel was subjected to centrifugation (4 °C, 100 g, 3
min) followed by two washes in 50 mM NaCl, 50 mM Tris, 0.1%
(v/v) TritonX-100, twowashes in 150mMNaCl, PBS, 0.1% (v/v)
Triton X-100, and two washes in PBS, 0.1% (v/v) Triton X-100.
The FLAG fusion proteins were eluted with 150 ng of 3FLAG
peptide (Sigma) for 30min at RT. The eluates were analyzed by
SDS-PAGE and immunoblotting. Approximately 10 g of pro-
tein was loaded into 4–12% (w/v) BisTris pre-cast gels (Invit-
rogen). Proteins were transferred to polyvinylidine fluoride
(PVDF) membranes (Millipore) and nonspecific binding was
blocked with 5% (w/v) skimmed milk in PBS plus 0.1% (v/v)
Tween 20 or with 20% (v/v) horse serum in PBS. Anti-myc
antibody (Sigma) was used at a 1:2,000 dilution and anti-FLAG
antibody (Sigma) was used at a 1:3,000 dilution at 4 °C over-
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night. For detection, a HRP-conjugated anti-rabbit secondary
antibody (Santa Cruz) was used at a 1:2,000 dilution together
with the SuperSignal West Pico Chemiluminescent Substrate
(Pierce).
GST Pull-downs—The human LRRK2 Roc domain (amino
acids 1328–1516) was cloned into a pGEX4T.1 vector with an
N-terminal GST tag using BamHI and XhoI restriction sites.
The recombinant GST and GST-Roc domains were expressed
in Escherichia coli BL21(DE3) (Novagen). Bacterial cultures
were grown at 37 °Cuntil theA600 reached 0.5 and then induced
with isopropyl -D-thiogalactopyranoside at a final concentra-
tion of 0.2 mM at 37 °C for 1.5 h. Cells were harvested and lysed
by sonication on ice in lysis buffer containing 50 mM Tris-HCl
(pH 7.4), 150 mMNaCl, 0.5 mM EDTA, 1 mMDTT, 0.1%, octyl-
-glucoside, 10% glycerol and protease inhibitors (Roche
Applied Science). After centrifugation for 20min at 12,000 g,
the supernatant was incubated with glutathione-Sepharose 4B
beads (Amersham Pharmacia Biosciences) overnight at 4 °C.
The beads were washed extensively twice with lysis buffer con-
taining 500 mM NaCl, then twice with lysis buffer containing
250 mM NaCl and twice with lysis buffer containing 150 mM
NaCl.
HEK293FT cells (Invitrogen) and human brain samples (cor-
tex) were lysed in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1% Triton, 10% glycerol and protease inhibitor mixture
(Roche Applied Science). Lysates were precleared by centrifu-
gation for 20 min at 12,000  g before pull-downs. 25 l of
glutathione-Sepharose 4B beads with 2g of purified recombi-
nant proteins (GST, GST-Roc) were incubated with 3 mg of
total cell or brain lysates for 2 h at 4 °C. After six washes (20mM
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 10% glycerol and
protease inhibitors), co-purified protein was eluted by addition
of 2 SDS sample buffer and then incubated at 95 °C for 5min.
Proteins were separated on 4–20% SDS-PAGE (Bio-Rad),
stained with Coomassie Brilliant Blue (Thermo Scientific), and
individual bands were excised for MS/MS identification.
Generation, Culture, and Western Blotting of Lrrk2 Knock-
out and Wild-type Control MEF Cells—Mouse skin primary
fibroblast cells (MEF)were derived from the dorsal skin of post-
natal day 0 (P0) wild-type or Lrrk2 knock-out mouse pups (38).
Minced skin was suspended in HEPES-buffered DMEM sup-
plementedwith 0.25% trypsin and 0.01%DNase I and incubated
at 37 °C for 20min. The tissueswere then transferred toDMEM
supplemented with 10% fetal bovine serum and dissociated by
repeated trituration. Cells were plated and immortalized by
transduction with large T antigen. The resulting cell colonies
were isolated and propagated individually to generate LRRK2
wild-type and knock-out stable cell lines. For transfection
experiments, MEF cells were grown in 6-cm plates and trans-
fected with 2 g of pRK5myc or pRK5mycLRRK2 using
FuGENE HD (Roche). Cells were harvested 24 h post-transfec-
tion in buffer containing 50 mM Tris, pH 7.5, 100 mMNaCl, 1%
TritonX-100, 1 complete protease inhibitormixture (Roche),
and 1 Halt phosphatase inhibitor mixture (Pierce). Lysates
were clarified by centrifugation at 14,000 g for 10min at 4 °C,
and supernatants were retained forWestern blot, performed as
above. Membranes were probed with mouse acetylated tubulin
antibody (6–11B-1; Sigma), rabbit /-tubulin antibody
(Pierce), and rabbit LRRK2 antibody (MJFF2; Epitomics) at
1:2,000 dilution. In all cases, membranes were probed first for
acetyltubulin, incubated for 30 min in stripping buffer (1.5%
(w/v) glycine, 1% Tween 20 and 1% SDS, adjusted to pH 2.2),
and then re-probed for total tubulin.
Culture and Immunocytochemistry of SH-SY5Y Cells—SH-
SY5Y cell lines stably over-expressing EGFP-LRRK2 wild-type
or EGFP-LRRK2 G2019S were made by lentiviral transduction
as described previously (39, 40). Cells were cultured in DMEM
supplemented with 1 non-essential amino acids (Invitrogen),
15% (v/v) FBS, and 1% (v/v) gentamycin. Neuronal differentia-
tion was induced by incubation in DMEM containing 1 non-
essential amino acids, 5% FBS, 1% (v/v) gentamycin, and 10 M
retinoic acid, with media replaced every 2 days. Wild-type
SH-SY5Y cells were cultured in DMEM/F-12 (1:1 Invitrogen)
supplementedwith 10% (v/v) FBS and 1% (v/v) penicillin/strep-
tomycin. SH-SY5Y cells were differentiated by treatment with
10 M retinoic acid and subsequent incubation for 4–7 days in
Neurobasal medium supplemented with 2 mM L-glutamine, 1%
(v/v) penicillin/streptomycin andB27 supplement (Invitrogen).
Cells were fixed using a cytoskeletal fixation method described
previously to allow extraction of all proteins not associatedwith
the cytoskeleton (41). Cells were stained with antibodies recog-
nizing LRRK2 (Michael J. Fox Foundation), or acetylated tubu-
lin (6–11B-1; Sigma) and counterstained with phalloidin and
DAPI for F-actin and nuclei, respectively.
Confocal Microscopy and Image Analysis—Confocal micros-
copy was performed using a Zeiss LSM 710 META. All images
were taken with a 63 objective. Fluorescence exited by the
488, 543, and 633 nm laser lines of argon and helium/neon
lasers was detected separately using only one laser at the time
(multitrack function) and a combination of bandpass filters (BP
505–530, BP 560–615), long pass (LP 560) filters, and meta
function (649–798) dependent on the combination of fluoro-
chromes used.
Molecular Modeling—Molecular modeling of the tubulin
structure was performed using Chimera (42). Amino acid sub-
stitutions were made with the swapaa command using the
Dunbrack backbone-dependent rotamer library (43) and taking
into account the lowest clash score, highest number of
H-bonds, and highest rotamer probability. For comparison
with the taxol binding site, the structure of /-tubulin dimers
bound to taxol was used (PDB 1JFF) (44). Because this com-
pound alters the surface conformation adjacent to the LRRK2
binding site, the remaining models used the structure of
unbound /-tubulin dimers (PDB 1TUB) (45).
Statistical Analysis—Growth cone width (Fig. 6I; n  10)
and filopodia number (Fig. 6J; n 10) were analyzed first by
two-way analysis of variance (ANOVA) to determine signif-
icant effects of cell type, differentiation time course, and the
interaction between cell type and differentiation. Statisti-
cally significant effects were further investigated by one-way
ANOVA. Tubulin acetylation (Fig. 7E; n  3) was analyzed
by unpaired Student’s t test with two-tailed distribution.
Quantitative yeast two-hybrid assays (Figs. 8, B and C (n 
5), D (n  6) and 9, A–C (n  4)) were analyzed using one-
way ANOVA. In all cases, combined data from aminimum of
three independent experiments was used. In all cases p val-
LRRK2 and-Tubulin
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ues are indicated (*, p  0.05; **, p  0.01; ***, p  0.001).
Error bars represent the mean  S.D.
RESULTS
The Roc Domain Interacts Directly with the C Terminus of
Specific -Tubulin Isoforms—Ayeast two-hybrid (YTH) screen
of a human whole brain cDNA library using a LRRK2 RocCOR
domain bait (19) revealed several independent cDNAclones for
the C terminus (Phe-317 to Ala-444) of the -tubulin isoform
TUBB4. This interaction was verified in co-immunoprecipita-
tion assays using full-lengthmyc-tagged LRRK2 and full-length
FLAG-tagged TUBB4 (Fig. 1A), and with the myc-tagged
LRRK2 RocCOR domain and the TUBB4 C terminus (Fig. 1B).
A similar interaction was seen between LRRK2 and another
-tubulin isoform, TUBB (Fig. 1, A and B).
In an independent screening technique, we recovered several
tubulin isoforms from HEK293 cell or mouse brain lysates by
glutathione pull-downs with a recombinant GST-Roc domain
protein (Fig. 2A). This refined the interaction to the Roc
domain (13). Confirming the localization of interaction, both
TUBB and TUBB4 interacted with the isolated LRRK2 Roc
domain in YTH assays but neither -tubulin bound the adja-
cent CORdomain (Fig. 1C). Furthermore, interferencewith the
Roc domain function by the introduction of a guanine nucleo-
tide non-binding mutation (K1347A) prevented association
with either -tubulin isoform, although self-interaction of the
RocCOR tandem domain was retained (Fig. 1D).
The above results suggest that in brain both- and-tubulin
isoforms can co-precipitate with LRRK2, but because tubulin
forms -/-heterodimers, either group of proteins could
directly interact with LRRK2. To resolve this, we used YTH
assayswith-tubulins that were precipitatedwith recombinant
GST-Roc (TUBA1A, TUBA1B, TUBA1C, and TUBA4A; Fig.
2A). None of the -tubulins studied were found to bind the
LRRK2 RocCOR tandem domain (Fig. 2B), suggesting direct
interaction is specific for -tubulin isoforms. The LRRK2
RocCORdomainalso failed to interactwith-or-actin (Fig. 2C).
Next, we tested all eight human -tubulin isoforms in YTH
assays. Besides TUBB and TUBB4, only one other -tubulin
was found to interact, TUBB6 (Fig. 2D). Because the extreme C
termini are themost diverse part of the-tubulin isoforms (Fig.
2E) we tested whether these regionsmight mediate the interac-
tions.We found that the region fromPhe-317 to theC terminus
of TUBB, TUBB4, and TUBB6 was sufficient for interaction
with the LRRK2 RocCOR tandem domain (Fig. 2D). However,
the extreme C terminus was not required for binding. C-termi-
nal deletion constructs (Phe-317 to Ala-430) did not abolish
interaction but increased protein-protein interaction strength
between -tubulins and LRRK2 in comparison to -tubulins
with intact C termini (Fig. 2F).
Having narrowed the LRRK2 interaction site on -tubulin to
a region between Phe-317 and Ala-430, we further compared
the amino acid sequences in this region (Fig. 3A). Intriguingly,
only three residues were conserved in the three interacting
-tubulins, but at least one of these residues was missing from
the non-binding-tubulin isoforms: Lys-362, Ala-364, and Ser-
371. Of the non-binding -tubulins, TUBB1 has serine at posi-
tion 362 and an asparagine at position 371, whereas TUBB2A,
TUBB2B, TUBB2C, and TUBB3 have a serine residue at posi-
FIGURE 1.The LRRK2RocGTPasedomainbinds TUBBandTUBB4.A, full-lengthmyc-tagged LRRK2 interactswith full-length FLAG-tagged TUBB and TUBB4
in co-immunoprecipitation experiments (CL, cell lysate; IP, anti-FLAG immunoprecipitates; transfections as indicated). B, the LRRK2 RocCOR domain and the
C termini of interacting -tubulin isoforms were sufficient for interaction. C, semiquantitative YTH experiments show interaction with TUBB and TUBB4 to
require the LRRK2 Roc but not COR domain. D, semiquantitative lacZ freeze-fracture assays show that the LRRK2 guanine nucleotide-bindingmutant K1347A
abolishes LRRK2 interactions with TUBB and TUBB4 but not LRRK2 RocCOR dimerization.
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tion 364. Introduction of a S362K substitution intoTUBB1 con-
ferred LRRK2 binding (Fig. 3B), confirming a requirement for
Lys-362. By contrast, mutation of Asn-371 to the serine present
in all other -tubulins (N371S) had no effect on binding (Fig.
3B). S364A mutations in TUBB2A, TUBB2B, TUBB2C, and
TUBB3 also permitted the direct association of these proteins
with LRRK2 (Fig. 3C), whereas the reciprocal A364S substitu-
tions inTUBB andTUBB4 abrogated binding (Fig. 3C).We also
introduced phosphomimeticmutations intoTUBB andTUBB4
(A364D, A364E). These negatively charged amino acids abol-
ished the interaction with LRRK2 in a similar manner to A364S
mutations (Fig. 3D). Thus, the binding of LRRK2 to -tubulins
requires two near adjacent residues, Lys-362 and Ala-364.
Because high-resolution crystal structures of -/-tubulin
heterodimers are available, we utilized a molecular modeling
approach to characterize the putative LRRK2 interaction sur-
face on-tubulin. Lys-362 is exposed at the protein surface, at a
location close to the -tubulin binding site for theMT-stabiliz-
ing compound taxol (Fig. 4, A and B). Both Lys-362 and the
taxol binding site are located on the luminal surface of mature
MT filaments. Further analysis revealed that the large positively
charged side chain of Lys-362 projects away from the rest of the
molecule (Fig. 4B). This observation is consistentwith a key role
for this amino acid in docking the LRRK2-tubulin interaction,
and in agreement with the failure of TUBB1 to bind LRRK2
(Figs. 2D and 3B).
Surprisingly, the second amino acid required for LRRK2
binding, Ala-364, is not exposed, residing just below Lys-362 at
the top of an internal -sheet (Fig. 4C). To determine whether
the presence of serine versus alanine at position 364 might al-
ter the external topology, hydrogen bond prediction was per-
formed (Fig. 4, C–E). Ala-364 appears unlikely to interact with
any neighboring residues (Fig. 4, C and E). By contrast, Ser-364
allows hydrogen bonding between the hydroxyl side chain of
this residue and the peptide backbone of the opposite strand of
the -sheet, at arginine 318 (Fig. 4D). This hydrogen bond
would be expected to increase stability at the top of the-sheet,
holding the protein loops immediately above in a more rigid
conformation. This, in turn, would likely affect the accessibility
of Lys-362. Thus we predict that the presence of serine or ala-
nine at position 364 governs LRRK2 binding by modulating
-tubulin surface topology and altering the position of Lys-362.
Surprisingly,mutation of the key residues Lys-362 orAla-364
to serine did not abolish interaction of LRRK2 with TUBB6
FIGURE 2. The direct interaction between LRRK2 and tubulin is specific to TUBB, TUBB4, and TUBB6. A,mass spectrometry of GST-Roc immunoprecipi-
tation from brain and HEK293 cell lysates identified -tubulin and -tubulin isoforms but not -actin as LRRK2 interactors. B, YTH assays show that the LRRK2
RocCOR tandem domain does not bind directly to the -tubulin isoforms TUBA1A, TUBA1B, TUBA1C, and TUBA4A; or C, - or -actin. D, LRRK2 binds directly
to the C termini of TUBB, TUBB4, and TUBB6but not to TUBB1, TUBB2A-C, or TUBB3. E, sequence alignment of the divergent extremeC-terminal tails of all eight
-tubulins. F, deletion of these C-terminal amino acid residues does not abolish the interaction between LRRK2 and -tubulin in YTH assays.
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(Fig. 5A). This suggested the presence of additional residue(s)
governing interaction in this -tubulin. Because molecular
modeling suggested the protein loop immediately above Arg-
318 might influence interaction with LRRK2 (Fig. 4, C–E) we
focused on differences betweenTUBB6 and other-tubulins in
this region. Intriguingly, all-tubulins except TUBB6 contain a
FIGURE 3. The LRRK2-tubulin interaction requires lysine 362 and alanine 364 of-tubulin. A, alignment of-tubulin isoforms reveals further sequence
divergence between residues 349 and 371. Note the presence of Lys-362 and Ala-364 in isoforms found to bind LRRK2 (TUBB, TUBB4, and TUBB6). B,mutation
S362K allows TUBB1 to bind LRRK2. C,mutation A364S in TUBB and TUBB4 abolishes the interaction of these proteins with LRRK2. By contrast, the reciprocal
S364A mutation in TUBB2A, TUBB2B, TUBB2C, and TUBB3 allows these -tubulins to interact with LRRK2. D, interaction of TUBB and TUBB4 with the LRRK2
RocCOR tandem domain is also abolished by phosphomimetic mutations at residue 364.
FIGURE4.Lysine362andalanine364of-tubulinchangetheconformationof theLRRK2bindingsite.A,modelingshows theLRRK2andtaxolbindingsitesare
in close proximity at the luminal surface of MTs. B,magnification of the area indicated in A. C-E, modeling of the structural influence of Lys-362 and Ala-364 versus
Ser-362 and Ser-364 on the accessibility of the LRRK2 binding site. C, Ala-364 in TUBB and TUBB4 is unlikely to form hydrogen bonds with arginine 318 allowing for
goodaccessibilityof Lys-362at theMTsurface.D,bycontrast, Ser-364 ispredicted to formahydrogenbondwitharginine318 restrictingLys-362conformation.E, the
shorter side chain of Ser-362 in comparison to Lys-362 at theMT surface is predicted to be unable to coordinate LRRK2 binding. A and B are derived from the crystal
structure of bovine/-tubulin dimers bound to taxol; C–E are derived from the crystal structure of unbound porcine/-tubulin dimers.
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large positively charged amino acid at position 320 (lysine in
TUBB1, arginine in the remaining -tubulins; Figs. 4,C–E, and
5,B and E). In TUBB6, this residue is a small, uncharged proline
(Fig. 5,B and E). Importantly, amino acids at this position are in
close proximity to Lys-362 at the microtubule surface (Fig. 5, C
and D) and are therefore likely to affect LRRK2 binding. Thus
we hypothesized that the presence of Pro-320 in TUBB6 was
sufficient to explain the different behavior of this -tubulin in
YTH assays. Similar to individual K362S and A364Smutations,
a P320R amino acid substitution had no effect on LRRK2 bind-
ing (Fig. 5A). However, when P320R was combined with the
K362SorA364Smutations,mimickingTUBB1 andTUBB2A/2B/
2C/3, respectively, the resultant TUBB6 proteins were unable to
bind LRRK2 (Fig. 5A). Thus Pro-320 of TUBB6 is permissive of
LRRK2 binding. Conversely, arginine at this position is inhibitory,
at least when combined with K362S or A364S mutations. Taken
together, this data confirms the reported association between
LRRK2andtubulins, anddemonstrates for the first timethat inter-
action is direct and specific to three -tubulin isoforms, TUBB,
TUBB4, andTUBB6. Interaction requires the LRRK2Roc domain
and is dependent on Lys-362 and Ala-364 within the -tubulin C
termini. The interaction is blocked in other-tubulin isoforms by
Ser-362 or the combination of Ser-364 and Arg-320, and also by
phosphomimetic amino acids at position 364 in TUBB and
TUBB4. Importantly, the interaction surface on-tubulins is pre-
dicted tobeadjacent to the taxol binding site at the luminal surface
of matureMT filaments.
The Direct Binding of LRRK2 to -Tubulin on the Luminal
Face of Microtubule Protofibrils Is Predicted to Affect Microtu-
bule Acetylation—Molecular modeling predicts that the
LRRK2 binding site on-tubulin is likely to be poorly accessible
to a large protein such as LRRK2. This suggests that LRRK2--
tubulin binding is more likely to occur among dynamic pools of
MTs. DynamicMTs are not acetylated, leading toweaker inter-
protofibril interactions (46), and a more open, flexible confor-
mation. The dynamic instability of MTs is crucial for growth
cone function and LRRK2 has previously been reported to
localize to growth cones (19). Here, we examined the associa-
tion betweenLRRK2 and growth cones in SH-SY5Y cells during
differentiation (Fig. 6).We comparedLRRK2 localization in cell
lines stably over-expressing EGFP-tagged wild-type LRRK2
(Fig. 6, E–H) with normal controls (Fig. 6, A–D). Using an
established fixation procedure designed to allow detection of
cytoskeletal structures (41), confocal microscopic analysis con-
firmed the presence of LRRK2 in growth cones. Endogenous
LRRK2 and EGFP-LRRK2 displayed similar patterns of local-
ization, and were detectable throughout the growth cone and
axon shaft, co-localizing with MTs (Fig. 6, A–H). LRRK2 was
predominantly localizedwithin the central zone (C-zone) of the
growth cone, the contrast between this and the relative lack of
FIGURE 5.Mutations to TUBB6 confirm the influence of arginine versus proline at residue 320 on interaction with LRRK2. A, the TUBB6 single mutants
P320R, K362S, or A364Sdonot abolish the LRRK2 interactionwith tubulin. Doublemutants P320R/K362Sor P320R/A364S in TUBB6 abolish the interactionwith
LRRK2. B, alignment of-tubulin isoforms reveals sequence divergence between TUBB6 and all other-tubulins at residue 320. C,modeling shows Arg-320 in
-tubulin in close proximity to the LRRK2binding residue Lys-362.D,magnification of the area indicated inC. E,modeling of the structural influence of Arg-320
versus Pro-320 on the accessibility of the LRRK2 binding site.
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LRRK2 at adjacent stabilized axonal MTs should be noted (Fig.
6, B and F). Thus LRRK2 appears to preferentially associate
with dynamic MTs, consistent with the notion that a direct
interaction site for LRRK2 is more accessible in this MT
population.
We also investigated growth cone parameters in SH-SY5Y
cells over-expressing wild-type or G2019S LRRK2 to a similar
extend and control cells during differentiation. Variables mea-
sured included growth cone width (Fig. 6I), length, volume, and
number of filopodia (Fig. 6J). Overall most parameters varied
widely, and initial differenceswere oftendiminishedover time, or
did not reach statistical significance. Nonetheless, two-way analy-
sis of variance of growth cone width revealed significant effects of
differentiation, cell type, and the interaction between these vari-
ables (p  0.001 in each case). Further investigation by one-way
ANOVA indicated that the effect of differentiation was entirely
restricted to growth cones of control cells, which widened signifi-
cantly throughout differentiation (Fig. 6I; p 0.001). By contrast,
increased growth cone width was not observed in cells over-ex-
pressing LRRK2 wild-type or the G2019S mutant (p 0.193 and
p  0.256, respectively). As a result, growth cones were signifi-
cantly smaller in over-expressing cells than controls at later time
points. Thus, LRRK2 over-expression had a pronounced inhibi-
tory effect on growth cone width expansion that appears to be
independent of the G2019Smutation.
By contrast, over-expression of wild-type and G2019S
LRRK2 had markedly different effects on the number of filop-
odia per growth cone (Fig. 6J). Differentiation did not alter
filopodia number (two-wayANOVA: p 0.378), nonetheless, a
highly significant effect of cell type was observed (p 0.001). In
comparison to control cells, LRRK2 wild-type over-expression
decreased the average number of filopodia per growth cone,
with significant differences measured at all time points. Con-
trastingly, cells over-expressing the G2019S mutant consis-
tently displayedmore filopodia than the LRRK2wild-type over-
expressing cell line (Fig. 6J). Overall, the over-expression of
LRRK2 wild-type and G2019S mutant has clear effects on
growth cone parameters, suggesting that LRRK2 has important
impacts on neurite outgrowth and synapse formation.
MT acetylation/deacetylation occurs on the luminal face of
-tubulin atLys-40 (47, 48). Because this residue is proximal to the
LRRK2 binding site on TUBB, TUBB4, and TUBB6 (Fig. 7,A and
B), we investigated whether a functional connection between
LRRK2expressionandMTacetylationexists.To this end, the level
of acetyl--tubulin in LRRK2knock-outMEFswas determinedby
Western blotting. Compared with a wild-type control cell line,
LRRK2 knock-out MEFs display a striking increase in tubulin
acetylation (Fig. 7,C–E). Importantly, transientover-expressionof
human wild-type LRRK2 in a subset of knock-out MEFs rescued
thisphenotype (Fig. 6,DandE).Note that a25%decrease inacetyl-
-tubulin compares very favorably with a maximal transfection
efficiency of40% observed under these conditions.7 These data
are consistent with a model where direct LRRK2 interaction with
TUBB, TUBB4, and TUBB6 on the luminal face of MTs is able to
modulate tubulin acetylation.
The R1441G LRRK2 Mutation and Mutations Mimicking
LRRK2 Roc Domain AutophosphorylationModulate Binding to
-Tubulin—Using co-immunoprecipitation, we investigated
the effect of a number of mutations in full-length LRRK2 on
7 D. C. Berwick and K. Harvey, unpublished data.
FIGURE6.LRRK2expression levels and theG2019Smutationaffectgrowthconedynamics.A–H, endogenous (A–D) and stablyoverexpressed (E–H) LRRK2
localizes preferentially to growth cones in SH-SY5Yneurites. Note the decline in expression levels proximal of the growth cones along the neurites. Scale bar 10
m. I, the increase in growth cone width during differentiation observed in control cells is abolished in cells over-expressing wild-type or G2019S mutant
LRRK2. J, thenumberof filopodiaper growth cone is decreased significantly in cells over-expressingwild-type LRRK2 in comparison to control cells. By contrast,
the number of filopodia per growth cone is increased significantly in cells over-expressing G2019Smutant LRRK2 in comparison to wild-type over-expressing
cells. *, p 0.05; **, p 0.01; ***, p 0.001; n 10.
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tubulin binding in HEK293 cells (Fig. 8A). Neither familial
LRRK2 nor artificial mutations in the Roc, COR, or kinase
domains of LRRK2 (T1348N, R1441C, Y1699C, G2019S,
K1906M), had statistically significant effects on LRRK2 inter-
action with -tubulin (Fig. 8A). Similar results were obtained
when co-precipitating -tubulin (data not shown). LRRK2
kinase inhibitors have been reported previously to modulate
the association of LRRK2 with MTs, albeit with contradictory
results (16, 18). In our hands, the LRRK2-in-1 kinase inhibitor
(49) failed to impact on LRRK2--tubulin interactions (Fig.
8A). Nonetheless, we observed a decrease in the interaction
between -tubulin and the LRRK2 G2019S mutant with
increased kinase activity that was rescued by pharmacological
inhibition of LRRK2 kinase activity (Fig. 8A, black box).
We hypothesized that co-immunoprecipitation might lack the
sensitivity to detect changes in LRRK2-tubulin interaction
strength. Thus, the effect of LRRK2 mutants on the interaction
with TUBB and TUBB4 was investigated using quantitative YTH
assays (Q-YTH; Figs. 8, B–D, and 9, A–C). Because LRRK2 auto-
phosphorylation within the Roc domain has been reported (50–
52),we investigated the effect of phosphomimetic amino acid sub-
stitutions at two Roc domain autophosphorylation sites on
LRRK2--tubulin interactions, asaproxy forelevatedkinaseactiv-
ity. Both mutants, T1343D and T1491D, weakened the interac-
tionswithTUBB/TUBB4by40–65%(Fig. 8,BandC).Mutation
of the same residues to alanine led to only a small reduction, no
reduction, or an increase of the interaction strength. Importantly,
noneof thesemutations influencedLRRK2RocCORdimerization
strength, demonstrating that these mutations did not influence
the Q-YTH results non-specifically (Fig. 8D).
We next investigated the effect on interaction with TUBB
and TUBB4 of PD-associated mutations in the LRRK2 Roc
domain. Interestingly, a LRRK2mutationwith proven pathoge-
nicity, R1441G, clearly reduced LRRK2-tubulin interactions by
50% (Fig. 9, A and B), as did R1441H albeit to a lesser extent
(25%). By contrast, R1441C appeared to increase LRRK2-tu-
bulin interactions by25%, whereas a LRRK2 variant not seg-
regating with PD (R1514Q) (53) showed no significant effect on
the interaction between LRRK2 and TUBB/TUBB4 (Fig. 8, A
andB). The R1441C, R1441G, R1441H and R1514Q amino acid
changes all decreased RocCOR dimerization strength between
60 and 80% (Fig. 9C) indicating that the results obtained for the
LRRK2-tubulin interactions are not the result of nonspecific
behaviors of the RocCOR baits in the Q-YTH assay. These data
are consistent with an inhibitory effect of selected Arg-1441
mutations and LRRK2 kinase activity on direct MT binding.
Because G2019S is known to increase LRRK2 kinase activity,
these observations strongly suggest that this mutation, like
R1441G or R1441H, will result in weakened LRRK2 binding to
-tubulin.
DISCUSSION
This study defines the interaction between LRRK2 and the
cytoskeleton, demonstrating that the LRRK2Roc domain binds
specifically to three neuronally expressed -tubulin isoforms,
TUBB, TUBB4, and TUBB6, but not the other common iso-
forms, TUBB1, TUBB2A/B/C, and TUBB3. This suggests that
LRRK2 distribution along MTs is determined by the tubulin
composition of MTs, in particular by the types of -tubulin
present. This specificity might also account for differences in
LRRK2 association with MTs in different brain regions or cell
types. We mapped the LRRK2--tubulin interaction surface to
a site centered around Lys-362, which is located on the same
surface of /-tubulin heterodimers as two sites important for
themodulation ofMT stability: the binding site for theMT-sta-
bilizing drug taxol on -tubulin (Fig. 4, A and B) and the MT
acetylation site on -tubulin at Lys-40 (Fig. 7, A and B). These
observations suggested that LRRK2binding toMTs couldmod-
ulateMT stability. Consistent with this view, LRRK2 knock-out
MEF cells show a marked increase inMT acetylation at the key
FIGURE 7. LRRK2 expressions correlates inversely with tubulin acetylation. A, modeling shows the LRRK2 binding site in close proximity to the Lys-40
acetylation site in -tubulin at the luminal surface of MTs. B, magnification of the area indicated in Fig. 6A. C, acetylation of Lys-40 in -tubulin is massively
increased in LRRK2 knock-out MEFs. D and E, the increase in acetylation in LRRK2 knock-out MEFs can be rescued by over-expression of human LRRK2. *, p
0.05; **, p 0.01; ***, p 0.001; n 3.
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-tubulin residue Lys-40 (Fig. 7,C–E), indicative of greaterMT
stability. Whether this represents increased acetylation or
decreased deacetylation (or a combination of both mecha-
nisms) cannot yet be determined. Nonetheless, it is interesting
to speculate as to the mechanism by which the LRRK2 protein
might decrease Lys-40 acetylation. In mammals, the major
enzyme catalyzing tubulin acetylation is the -tubulin Lys-40
acetyltransferase (also known as MEC-17) (47, 54), whereas
deacetylation is carried out by two enzymes, histone deacety-
lase 6 (HDAC6) (48, 55, 56) and sirtuin2 (SIRT2) (57). In prin-
ciple LRRK2 could alter the activity of any one of these
enzymes, for example, via protein-protein interaction, or alter-
natively via phosphorylation. However, given the large size of
LRRK2 (see following paragraph), we would suggest that the
most likely explanation is that LRRK2 simply prevents -tubu-
lin Lys-40 acetyltransferase from accessing Lys-40, thereby
keeping-tubulin in a non-acetylated state. Clearly, these ideas
require further testing. Nonetheless, we conclude that LRRK2-
tubulin interactions affectMTacetylation and thereby promote
MT destabilization.
We also note that Lys-362 has been reported to be a site of
ubiquitination in two proteomic studies (TUBB2B, TUBB3, and
TUBB6 (58); TUBB,TUBB2C,TUBB3,TUBB4, andTUBB6 (59)).
Ubiquitinated Lys-362 would be predicted to block LRRK2 asso-
ciation with MTs. Therefore, a dynamic regulation of LRRK2--
tubulin interactions and by extensionMT acetylation via Lys-362
ubiquitination in TUBB, TUBB4, and TUBB6 is plausible.
Our hypothesis is that LRRK2--tubulin binding interferes
with tubulin acetylation and occurs predominantly in dynamic
pools of MTs with a more open, flexible conformation (46).
Consistentwith this idea, we found a preferential localization of
LRRK2 to MTs within growth cones, rather than adjacent stable
FIGURE 8. LRRK2 Roc domain autophosphorylation interferes with the LRRK2-tubulin interaction. A, Western blot showing a decrease of the LRRK2--
tubulin interaction in co-immunoprecipitation experiments with the G2019S mutant in comparison with wild-type LRRK2 (black box). This decrease was
rescued by LRRK2 kinase inhibition with LRRK2in1. B–D, quantitative YTH assays show that the introduction of phosphomimetic mutations at Roc domain
autophosphorylation sites decreases the interaction with TUBB4 (B) and TUBB (C) but has no effect on RocCOR dimerization (D). Introduction of an alanine at
the autophosphorylation sites has less and more diverse effects on the interactions shown. *, p 0.05; **, p 0.01; ***, p 0.001; n 5–6.
FIGURE 9. Familial LRRK2mutations affect the LRRK2-tubulin interaction. A and B, quantitative YTH assays show that the introduction of familial LRRK2
mutations can increase (R1441C) as well as decrease (R1441G/H) the interaction with TUBB4 (A) and TUBB (B), whereas the R1514Q amino acid change, which
does not segregatewith PD, has no statistically significant effect.C, all amino acid changes decrease the RocCORdimerization strength. *, p 0.05; **, p 0.01;
***, p 0.001; n 4.
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MTs in axons (Fig. 6,B and F). Growth cone function relies on the
dynamic instability of MTs and dynamic MTs display weaker
interprotofibril associations. This creates greater luminal space,
allowing for the binding of a large molecule such as LRRK2.
LRRK2--tubulin interactions are likely to be of functional rele-
vance to growth cone biology, because over-expression of LRRK2
during differentiation results in a reduction in growth cone width
(Fig. 6I) and number of filopodia per growth cone (Fig. 6J). None-
theless, the location of the LRRK2 binding site on-tubulins does
raise thequestionofwhether this proteinmight interactwithMTs
within mature, stable MT tracts, such as those in axons. It should
be noted that the presence of protein complexes within MT fila-
ments iswell supported in the literature. Indeed, theMAPTauhas
been demonstrated to partially reside inside this compartment
(60). However, whereas LRRK2 seems able to access the lumen of
dynamicMT structures at growth cones, we would suggest that it
is less likely thatLRRK2canaccess the-tubulinbinding site along
the entire length of neurites within the MT lumen. An electron
microscopic study of cross-sectionedMT filaments inDrosophila
revealed an average internal area of 244 nm2, indicating thatMTs
with an internal diameter greater than 19nmare extremely rare in
nature (46). Assuming a tubulin width of6.5 nm (46), this inter-
nal diameter can be considered equivalent to three tubulinmono-
mers at most. The crystal structure of LRRK2 has not been
resolved and thus the physical size of this protein is
unknown. Nonetheless, at 2527 amino acids in length,
LRRK2 is over five times the size of a tubulin monomer. Thus
it seems likely that LRRK2 is too large to enter this compart-
ment. In conclusion, LRRK2 appears to bind directly to the
lumen of MTs interfering with tubulin acetylation in vivo.
This binding is likely restricted to locations where MT
protofibrils are held in an “open” confirmation.
We also demonstrated that the Roc-domain R1441G (and
the less frequent familial R1441H) mutant with proven patho-
genicity disrupted LRRK2--tubulin interactions, whereas the
R1441C variant increased LRRK2--tubulin interactions. A
trend toward an increased LRRK2--tubulin interaction for the
R1441C mutant was previously reported (13). By contrast, the
non-segregating R1514Q variant (53), showed no influence on
LRRK2--tubulin interactions (Fig. 9). This observation sug-
gests that altered LRRK2--tubulin interactions are likely to
occur in patients with these LRRK2 mutations. This suggests
that the interaction between LRRK2 andMTs requires fine reg-
ulation, and that both decreased and increased interaction
strength could affect the dynamic instability of MTs. Both
increased and decreased MT stability are detrimental, well
illustrated by the effect of anticancer chemotherapeutic medi-
cation increasing (e.g. taxol) or decreasing (e.g. vincristine) MT
stability. Interestingly, interaction strength was also markedly
weakened by two mutations (T1343D, T1491D) mimicking
LRRK2 autophosphorylation within the LRRK2 Roc domain
(Fig. 8, B and C). These phosphomimetic mutants serve as a
proxy for increased LRRK2 kinase activity, which cannot be
tested directly in the RocCOR tandem domain constructs used
in our YTH assays. Importantly, elevated kinase activity has
been a consistent observation for the most common G2019S
LRRK2 mutation, and thus these data suggest the G2019S
mutationwill also lead to decreased luminalMTbinding. Thus,
our data indicate that three pathogenic LRRK2 mutations,
G2019S, R1441G, and R1441H, are likely to cause reduced
LRRK2--tubulin interactions. Interestingly, effects of over-ex-
pression of wild-type LRRK2, the R1441G andG2019Smutants
on the expression and phosphorylation of the MAP Tau were
shown previously (32, 33), whereas in R1441C knock-in mice
no effect on Tau expression or phosphorylation was observed
(61). This might be an effect of R1441G over-expression in
comparison to endogenous expression levels of the R1441C
mutant in knock-in mice, but might also correspond to differ-
ent effects of these mutants on the interaction between LRRK2
and MTs as suggested in this study (Fig. 8, A and B).
Intuitively, one would expect processes relevant to PD patho-
genesis to bemodulated similarly by all LRRK2mutants segregat-
ing with the disease. However, different effects of LRRK2mutants
have been described previously in numerous cellular and bio-
chemical assays. These include opposite effects onmeasurements
of LRRK2kinase activity andprotein-protein interaction strength,
for example,with14-3-3 andDVLproteins (8, 19, 62).As such, it is
perhaps more likely that PD-relevant processes perturbed by
LRRK2 mutants are under fine regulation, with “too much” and
“too little” equally able to elicit neurodegeneration. It is thus fasci-
nating thatMToverstabilization anddestabilizationwill have det-
rimental effects on numerous MT-dependent processes. Taken
together therefore, ourdata shed lighton thecells biological roleof
the LRRK2-tubulin interaction, and indicate that alterations in
microtubule stability caused by changes in LRRK2 could contrib-
ute to the pathogenesis of PD.
Mutations in human tubulin genes have been found in a
number of genetic disorders. These include lissencephaly/SBH
(TUBA1A) (63, 64), asymmetric polymicrogyria (TUBB2B)
(65), and the ocular motility disorder CFEOM3 (TUBB3) (66–
68). Most intriguingly, however, an R2G amino acid substitution
in TUBB4 has recently been reported as causing the rare move-
ment disorder, dystonia type 4 (also known aswhispering dyspho-
nia) (69, 70). This mutation was found to elicit a decrease in
TUBB4 expression (69, 70). Because our work has established
LRRK2as adirect interactor ofTUBB4, onemight expect dystonia
type 4patients to display decreasedLRRK2 localization toMTs. In
light of the likely decrease in LRRK2MT binding in R1441G and
G2019S carriers, this is an intriguing possibility, suggesting that
LRRK2 might be connected to the pathogenesis of an additional
movement disorder. This also suggests the possibility that muta-
tions in human tubulin genesmight be a genetic risk factor for PD,
and we would contend that a genetic analysis of selected tubulin
genes (particularly TUBB, TUBB4, and TUBB6) in PD patients is
warranted. In any case, it is fascinating that proteins encoded by
two genes linked to familial movement disorders should interact
directly, suggesting the possibility of a commonpathomechanism,
and highlighting the potential importance of the LRRK2--tubu-
lin interaction.
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